InterMune to Release Fourth Quarter, Full Year 2007 Financial Results on February 7

Friday, January 25, 2008 General News
Email Print This Page Comment
Font : A-A+

BRISBANE, Calif., Jan. 24 InterMune, Inc.(Nasdaq: ITMN) announced today that it will release fourth quarter andfull-year 2007 financial results on Thursday, February 7, 2008 at 4:00 p.m.Eastern time. A live conference call and webcast will be hosted by InterMuneat 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or706-634-0154 (international), conference ID#32601453. To access the webcast,please log on to the company's website at http://www.intermune.com at least 15minutes prior to the start of the call to ensure adequate time for anysoftware downloads that may be required.

A replay of the webcast and teleconference will be available approximatelythree hours after the call. The teleconference replay will be available for10 business days following the call and can be accessed by dialing800-642-1687 (U.S.) or 706-645-9291 (international), and entering theconference ID#32601453.

About InterMune

InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolioincludes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as apossible therapeutic candidate for the treatment of patients with IPF and aresearch program focused on small molecules for pulmonary disease. Thehepatology portfolio includes the HCV protease inhibitor compound ITMN-191(R7227) in Phase 1b, a second-generation HCV protease inhibitor researchprogram, and a research program evaluating a new target in hepatology. Foradditional information about InterMune and its R&D pipeline, please visithttp://www.intermune.com.

SOURCE InterMune, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook